Recherche
Enseignement
Solutions
S'identifier
FR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
School of Pharmaceutical Sciences,
Center for Cellular & Structural Biology
Jiayu Liu has not added Biography.
If you are Jiayu Liu and would like to personalize this page please email our Author Liaison for assistance.
A targeted IL-15 fusion protein with potent anti-tumor activity.
Cancer biology & therapy , 2015 | Pubmed ID: 26176990
BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.
Translational oncology Oct, 2017 | Pubmed ID: 28797938
A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
Journal of immunotherapy (Hagerstown, Md. : 1997) Jan, 2018 | Pubmed ID: 29232309
Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.
PloS one , 2018 | Pubmed ID: 29357376
A Single Domain-Based Anti-Her2 Antibody Has Potent Antitumor Activities.
Translational oncology Apr, 2018 | Pubmed ID: 29455083
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.
International journal of nanomedicine , 2018 | Pubmed ID: 29881272
A HER2 bispecific antibody can be efficiently expressed in with potent cytotoxicity.
Oncology letters Jul, 2018 | Pubmed ID: 29963199
Sun Yat-sen University
Yanlan Wang1,2,
Jiayu Liu1,2,
Haitao Pan1,2,
Jieyu Xing1,2,
Xiaoqiong Wu1,2,
Qing Li1,2,
Zhong Wang1,2
1School of Pharmaceutical Sciences, Sun Yat-Sen University,
2Center for Cellular & Structural Biology, Sun Yat-Sen University
Confidentialité
Conditions d'utilisation
Politiques
Contactez-nous
RECOMMANDER À LA BIBLIOTHÈQUE
NEWSLETTERS JoVE
JoVE Journal
Collections de méthodes
JoVE Encyclopedia of Experiments
Archives
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centre de ressources universitaires
Auteurs
Bibliothécaires
Accès
À PROPOS DE JoVE
Copyright © 2024 MyJoVE Corporation. Tous droits réservés.